Expert Review of Anti-infective Therapy最新文献_第5页

The changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios. 亚太地区念珠菌种类的流行病学变化以及在具有挑战性的临床情况下优化抗真菌剂量的证据。

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-31 DOI: 10.1080/14787210.2025.2539427

Yee-Chun Chen, Sohita Dhillon, Nicholas Adomakoh, Jason A Roberts

{"title":"The changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios.","authors":"Yee-Chun Chen, Sohita Dhillon, Nicholas Adomakoh, Jason A Roberts","doi":"10.1080/14787210.2025.2539427","DOIUrl":"10.1080/14787210.2025.2539427","url":null,"abstract":"Introduction: The global burden of invasive fungal infections (IFIs) is increasing, with the threat of disease exacerbated by the emergence of antifungal resistance. While antifungals remain the mainstay for the treatment of IFIs, there is a growing recognition of the many patient variables, particularly in challenging situations (e.g. critically ill patients), that can impact the exposure of antifungals.Areas covered: This narrative review focuses on the changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios, based on a symposium held at the International Society for Human and Animal Mycology Asia Congress in Bangkok, Thailand, on 1 August 2024.Expert opinion: Antifungal resistance is common and increasing among fungal pathogens (e.g. Candida species) in the Asia Pacific. Optimal drug selection and dosing of antifungals is critical for achieving the best therapeutic outcomes and limiting resistance emergence, particularly in challenging clinical scenarios. Current 'standard' doses of antifungals do not account for pharmacokinetic variations in critically ill patients and can lead to suboptimal exposures, highlighting the need for better dosing regimens in these patients. Therapeutic drug monitoring is a valuable strategy for optimizing antifungal therapy, and its use is encouraged, particularly in critically ill patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":3.8,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Women trailblazers shaping the global future of antimicrobial stewardship and antimicrobial resistance. 塑造抗菌素管理和抗菌素耐药性全球未来的女性开拓者。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-06 DOI: 10.1080/14787210.2025.2530623

Debra A Goff, Afreenish Amir, Diane Ashiru-Oredope, Ella Balasa, Vanessa Carter, Angela Dramowski, Diane Flayhart, Souha Kanj, Flavia Rossi, Natalie Schellack, Diane Shader Smith, Karin Thursky, Dena van den Bergh, María Virginia Villegas

引用次数: 0

Cause and effect? A review of the impact of antibiotics on the gut microbiome in patients undergoing hematopoietic stem cell transplantation. 因果关系？抗生素对造血干细胞移植患者肠道微生物组影响的综述

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-06 DOI: 10.1080/14787210.2025.2527970

Midori Nakagaki, Krispin Hajkowicz, Jason A Roberts, Andrea S Henden

{"title":"Cause and effect? A review of the impact of antibiotics on the gut microbiome in patients undergoing hematopoietic stem cell transplantation.","authors":"Midori Nakagaki, Krispin Hajkowicz, Jason A Roberts, Andrea S Henden","doi":"10.1080/14787210.2025.2527970","DOIUrl":"10.1080/14787210.2025.2527970","url":null,"abstract":"Introduction: Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk of infection due to immunosuppression, prompting routine use of prophylactic and broad-spectrum antibiotics for treatment. However, emerging evidence suggests that gut microbiome disruption (dysbiosis), partly caused by antibiotic use, is associated with poorer transplant outcomes, including graft-versus-host disease (GVHD), infection, and mortality.Areas covered: This narrative review discusses antibiotic use to prevent and treat febrile neutropenia in allo-HSCT recipients, including effectiveness, impacts on microbiome and GVHD, antimicrobial resistance and Clostridioides difficile infection (CDI). It also reviews available strategies to reduce unnecessary antibiotic use and proposes potential future interventions. A comprehensive PubMed search was conducted through 2024 using terms related to HSCT, antimicrobials, microbiome, resistance, and CDI.Expert opinion: Improving outcomes while minimizing emergence of antibiotic resistance and CDI requires personalized, risk-adaptive antimicrobial stewardship (AMS). Tailored AMS approaches, including patient risk stratification and early de-escalation, could limit unnecessary antibiotic use and mitigate adverse effects. In the future, microbiome preservation and restoration may reduce transplant complications by maintaining colonization resistance and immune balance. Integrating these strategies into allo-HSCT care is essential for optimizing both clinical and microbiological outcomes.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":4.2,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow. 关键的重新评估当前的问题，以提高正确的临床使用即将到来的β -内酰胺/ β -内酰胺酶抑制剂组合的明天。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-04-16 DOI: 10.1080/14787210.2025.2493077

Milo Gatti, Federico Pea

{"title":"Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow.","authors":"Milo Gatti, Federico Pea","doi":"10.1080/14787210.2025.2493077","DOIUrl":"10.1080/14787210.2025.2493077","url":null,"abstract":"Introduction: Although different novel beta-lactam/beta-lactamase inhibitor combinations (BL/BLIc) were recently licensed, resistance occurrence have been reported up to 15% of Gram-negative pathogens. For this reason, novel BL/BLIc of tomorrow will be released for managing difficult-to-treat resistance (DTR) Gram-negative infections.Areas covered: This review provides a critical reappraisal of current issues for improving the proper clinical use of the novel BL/BLIc of tomorrow. A literature search was performed on PubMed-MEDLINE (until December 2024) for retrieving available studies on cefepime-enmetazobactam, sulbactam-durlobactam, and cefepime-taniborbactam. Four different main areas were discussed according to available evidence: 1) translating findings coming from the randomized clinical trials into the real-world clinical practice; 2) defining the optimal joint pharmacokinetic/pharmacodynamic (PK/PD) target; 3) identifying proper dosing schedules in patients with renal dysfunction; 4) attributing proper relevance to the epithelial lining fluid (ELF) penetration rate in defining optimal dosing schedule for treating pneumonia.Expert opinion: Overall, old habits die hard and issues retrieved with licensed beta-lactams emerged also with novel BL/BLIc of tomorrow, potentially affecting their efficacy when used in real-world practice. Adopting appropriate corrective measures for overcoming these issues might increase the likelihood of preserving their efficacy in the future by minimizing the propensity risk of resistance development.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"433-443"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-drug resistant tuberculosis: where should we be with optimal treatment? 耐多药结核病：我们应该在哪里获得最佳治疗？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-19 DOI: 10.1080/14787210.2025.2506777

Emanuele Pontali, Rosella Centis, Lia D'Ambrosio, Denise Rossato Silva, Daria Podlekareva, Giovanni Battista Migliori

引用次数: 0

Letter to the Editor: the earliest observation of bla_NDM was in Israel. 致编辑的信：最早观察到blaNDM是在以色列。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-28 DOI: 10.1080/14787210.2025.2510284

Louis-Patrick Haraoui

引用次数: 0

An overview of potential combination therapies with ceftriaxone as a treatment for gonorrhoea. 头孢曲松作为淋病治疗的潜在联合疗法综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-19 DOI: 10.1080/14787210.2025.2505559

Izumo Kanesaka, Fabian Yuh Shiong Kong, Thibaut Vanbaelen, Sheeba Santhini Manoharan-Basil, Chris Kenyon

{"title":"An overview of potential combination therapies with ceftriaxone as a treatment for gonorrhoea.","authors":"Izumo Kanesaka, Fabian Yuh Shiong Kong, Thibaut Vanbaelen, Sheeba Santhini Manoharan-Basil, Chris Kenyon","doi":"10.1080/14787210.2025.2505559","DOIUrl":"10.1080/14787210.2025.2505559","url":null,"abstract":"Introduction: Ceftriaxone is the last available single dose therapy for gonorrhea that effectively treats infections at all sites. Over a quarter of isolates are now resistant to ceftriaxone in some countries. The introduction of carefully chosen combination therapy with ceftriaxone could retard the emergence of ceftriaxone resistance.Areas covered: This review summarizes the findings of a PubMed search on the use of partner antimicrobial that could be used with ceftriaxone to prevent the emergence and spread of ceftriaxone resistance. We review 16 antimicrobials that could be partnered with ceftriaxone in terms of pharmacokinetic and pharmacodynamic compatibilities, activity against ceftriaxone resistant isolates and probability of antimicrobial resistance emerging.Expert opinion: Of these 16 antimicrobials, we reject antimicrobials such as fosfomycin due to poor clinical efficacy and tigecycline due to its considerably longer half-life which would likely select for tetracycline resistance. The most promising agents for combination with ceftriaxone are zoliflodacin, delafloxacin, sitafloxacin, eravacycline and possibly gepotidacin and gentamicin. Clinical studies should be conducted to evaluate the efficacy of these combinations on the eradication of N. gonorrhoeae and their impact on AMR in N. gonorrhoeae and other bacterial species.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"459-467"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence and predictors of linezolid-associated thrombocytopenia in critically ill patients: nomogram development based on comprehensive screening of over 70 factors. 危重患者利奈唑胺相关血小板减少症的发病率和预测因素：基于70多种因素综合筛选的线图发展

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-05 DOI: 10.1080/14787210.2025.2500589

Abdel-Hameed Ebid, Mohamed Abdeltawab, Osama Ahmed, Mohamed A Mobarez, Mahmoud Ibrahim

{"title":"Incidence and predictors of linezolid-associated thrombocytopenia in critically ill patients: nomogram development based on comprehensive screening of over 70 factors.","authors":"Abdel-Hameed Ebid, Mohamed Abdeltawab, Osama Ahmed, Mohamed A Mobarez, Mahmoud Ibrahim","doi":"10.1080/14787210.2025.2500589","DOIUrl":"10.1080/14787210.2025.2500589","url":null,"abstract":"Background: Linezolid-associated thrombocytopenia (LAT) is a significant complication in intensive care unit (ICU) patients, increasing bleeding risk and leading to treatment discontinuation. This study aims to assess LAT incidence, identify risk and protective factors, and develop a predictive nomogram.Research design and methods: This retrospective cohort study included 422 adult ICU patients treated with linezolid. Over 70 clinical, demographic, laboratory, and therapeutic variables were analyzed. Logistic regression identified key risk and protective factors for LAT, and a nomogram was developed for risk prediction.Results: LAT occurred in 39.8% of patients. Risk factors included linezolid therapy > 10 days (OR 5.80, p < 0.01), solid organ tumor (OR 2.18, p = 0.03), hemodialysis (OR 5.12, p < 0.01), elevated lactate (OR 1.13, p = 0.03), and vasopressor use (OR 4.48, p < 0.01). Protective factors were surgery (OR 0.34, p < 0.01), IV N-acetylcysteine (OR 0.12, p < 0.01), oral N-acetylcysteine (OR 0.17, p < 0.01), higher baseline platelets (OR 0.79, p = 0.05), and acetaminophen (OR 0.42, p < 0.01). The nomogram showed strong discrimination (AUC 0.834, p < 0.001).Conclusions: LAT is common in ICU patients and associated with adverse outcomes. Prolonged therapy, solid organ tumors, dialysis, high lactate, and vasopressor use increase risk; high platelet counts, N-acetylcysteine, and IV acetaminophen decrease risk. External validation and prospective trials are warranted.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"499-511"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of clinical outcomes of antibiotics used for Staphylococcus aureus bacteremia in pediatric patients. 抗生素治疗儿科金黄色葡萄球菌菌血症的临床效果比较。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-04-16 DOI: 10.1080/14787210.2025.2493075

Ömer Güneş, Saliha Kanık-Yüksek, Aylin Kayalı-Akyol, Özhan Akyol, Ahmet Yasin Güney, Fatih Üçkardeş, Aysun Yahşi, Seval Özen, Tuğba Erat, Belgin Gülhan, Gülsüm İclal Bayhan, Aslınur Özkaya-Parlakay

{"title":"Comparison of clinical outcomes of antibiotics used for Staphylococcus aureus bacteremia in pediatric patients.","authors":"Ömer Güneş, Saliha Kanık-Yüksek, Aylin Kayalı-Akyol, Özhan Akyol, Ahmet Yasin Güney, Fatih Üçkardeş, Aysun Yahşi, Seval Özen, Tuğba Erat, Belgin Gülhan, Gülsüm İclal Bayhan, Aslınur Özkaya-Parlakay","doi":"10.1080/14787210.2025.2493075","DOIUrl":"10.1080/14787210.2025.2493075","url":null,"abstract":"Background: This study aims to evaluate the risk factors, clinical features, and clinical outcomes among pediatric hospitalized patients receiving treatment for Staphylococcus aureus bacteremia and compare the effects of antibiotics used in the treatment on clinical outcomes.Research design and methods: This single-center retrospective study included patients aged between 1 month and 18 years who received treatment for Staphylococcus aureus bacteremia (SAB) betweenSeptember 2019 and September 2022.Results: SAB was detected in 95 pediatric patients. In MRSA bacteremias, no difference in clinical outcomes was found between patients receiving vancomycin or teicoplanin. In MSSA bacteremias, the recurrence rate of SAB was 0% in the penicillin group and 23.5% in the cephalosporin group. The median duration of bacteremia-related hospital stay (10 vs. 14 days), and the median duration of bacteremia (2 vs. 3 days) were shorter in the ampicillin-sulbactam group than in the piperacillin-tazobactam group (p = 0.016, and p = 0.050, respectively).Conclusions: Teicoplanin was found to have similar clinical outcomes to vancomycin in treating MRSA bacteremia. In addition, ampicillin sulbactam was found to have better clinical outcomes than other antibiotics in treating MSSA bacteremia. Teicoplanin and ampicillin sulbactam may be considered as a choice in the treatment of pediatric SAB.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"491-498"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Doxycycline post-exposure prophylaxis as prevention of STIs - the golden bullet? 多西环素暴露后预防是预防性传播感染的黄金子弹？

IF 3.8 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-25 DOI: 10.1080/14787210.2025.2510278

Manik Kohli, Thomas Elliott-Walker, John Saunders, Helen Fifer

{"title":"Doxycycline post-exposure prophylaxis as prevention of STIs - the golden bullet?","authors":"Manik Kohli, Thomas Elliott-Walker, John Saunders, Helen Fifer","doi":"10.1080/14787210.2025.2510278","DOIUrl":"10.1080/14787210.2025.2510278","url":null,"abstract":"Introduction: Doxycycline post-exposure prophylaxis ('doxyPEP') is an emerging strategy to prevent bacterial sexually transmitted infections (STIs). Users take 200 mg of doxycycline up to 72 hours after condomless sex, and data from randomized controlled trials and real-world implementation have shown doxyPEP to be effective in preventing syphilis, chlamydia, and to a lesser extent gonorrhea, in gay, bisexual, and other men-who-have-sex-with-men (GBMSM) and transgender women.Areas covered: We discuss the potential benefits, risks, and important considerations for doxyPEP implementation, drawing on published literature and our own perspectives.Expert opinion: Is doxyPEP the golden bullet? DoxyPEP provides significant benefits through STI prevention and holistic improvements in sexual health and wellbeing. Concerns over emergent antimicrobial resistance need to be weighed against STI-related morbidity and contextualized within society's overuse of antibiotics. Inequities in the doxyPEP evidence-base and implementation will undermine its ability to end the syphilis epidemic and reduce chlamydia associated morbidity in cisgender women. Moreover, contexts in which doxyPEP proves effective for gonorrhea prevention initially are unlikely to see a long-lasting impact. Rather than a golden bullet, doxyPEP is a bridge to the next set of STI prevention tools.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"445-457"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0